Banner

What's New

Innovative resource for your improved understanding of
specialty diseases

Monthly Archives: June 2016

June 2016 OncoPoll – GI Cancers

MDoutlook proudly continues our innovative initiative of syndicated research analyzing the clinical impact of new data presented at the 2016 ASCO Annual Meeting®. Supporting the entire cancer community and building on nearly 40 analyses since 2008, this is the first report in our 2016 series covering new clinical data presented in Chicago.

This OncoPoll™ focuses on the gastrointestinal tumors, focusing on 4 abstracts in colorectal and pancreatic cancers. Our most recent research from 134 global oncologists managing GI cancer patients uncovers that:
• Data presented in 3 abstracts on primary tumor sidedness in metastatic colorectal cancer is reported as clinically meaningful.
• Changes in treatment selections will primarily occur only for left-sided tumors, with a 38% increase in the use of FOLFOX or FOLFIRI + cetuximab, with a 9% decrease in the use of bevacizumab in these patients
• Oncologists assign high importance to data presented on the addition of capecitabine to gemcitabine in the adjuvant setting for resected pancreatic cancer
• Gemcitabine + capecitabine (GEMCAP) is expected to become the standard of care in the adjuvant setting for resectable pancreatic cancer, with ~ half of all patients receiving it moving forward
• Integration of these results into clinical practice are going to happen in relatively short order, especially since agents are already widely available and in use

Download your complimentary copy of our report MDoutlook June 2016 Oncopoll – GI Cancers.

MDoutlook continues its commitment to all stakeholders involved in the management of cancer to provide actionable and timely insight. As in previous years, we work with Oncology Business Review to share this important research with the cancer community.

To discuss your oncology and disease intelligence needs, please contact us at [email protected] or +1.404.496.4136. Thank you!

Submitted by Dr. Robert Stephan, Vice President, Research and Physician Society, and Jan Heybroek, President of MDoutlook. All Rights Reserved ©2016. All registered trademarks are the property of their respective owners.

Post-Chicago 2016 Excitement – Global Physician Reactions

Before the 2016 ASCO Annual Meeting® started, we asked oncologists about which tracks they were most excited. With the annual neeting behind us, we followed up to find out which tracks actually delivered on that excitement. Included in our Post-Chicago OncoPoll™ were a few questions: “Did you attend this year’s annual meeting in Chicago?” and “About which therapy track(s) were you most excited?”.

MDoutlook® is pleased to share excerpts from this most recent MDoutlook OncoPoll™ series on the oncologists reactions to the data presented in Chicago.

OncoPoll™ Methodology

  • Primary research phase involved global survey to verified and validated medical, hematologic, surgical, and radiation oncologists within the proprietary MDoutlook® global cancer treater panel
  • Fielded: June 8th through 13th
  • Research via interactive web-based survey instruments, utilizing proven MDoutlook methodology and proprietary technology
  • Aided list of Annual Meeting tracks was provided from which to choose
  • Response: 132 oncologists

Key Conclusions: Overall Post-Meeting Reactions for 2016 Annual Meeting in Chicago

  • Overall, there was more excitement about the individual tracks before the meeting, than once the data were presented
  • Physicians are now most excited about the new data in metastatic NSCLC announced at the conference

Post Meeting Excitement

Conclusions

  • The top mentioned track was metastatic NSCLC, with 39% of respondents choosing this as an area of excitement in the annual meeting
  • The next 5 tracks were tied for 2nd place, with 33-34% of respondents choosing these areas
  • Genitourinary (Nonprostate) Cancer caused the most excitement outside of the US, but only ranked 10th in the US

Regional Differences in Post-ASCO Excitement

Conclusions

  • Looking specifically at those tracks selected by more than 30% of the respondents, one gets the overall impression that the level of excitement continues to be higher in the US than in other regions
    • Genitourinary (Nonprostate) Cancer is the exception, with the US oncologists far less enthusiasm than the ex-US physicians
  • Overall, the most excitement is with the US oncologists and Metastatic NSCLC, likely because of the J-ALEX data announcement

Comparison Pre- and Post-ASCO Excitement

Conclusions

  • The pre-ASCO excitement was not sustained for most tracks
  • The greatest disappointment was with Breast Cancer – HER2/ER, with 13% fewer oncologists having post-conference excitement about the track than had anticipation for it
  • Genitourinary (Nonprostate) Cancer track produced the most positive difference in excitement after the conference than before

For More Information

We are conducting our annual series of OncoPolls to assess the immediate impact of the meeting on clinical practice. Please look for these reports to be published here in the near future. You can download a PDF copy of the report here.

To discuss your oncology intelligence needs, please contact us at [email protected] or +1.404.496.4136. Thank you!

Submitted by Dr. Robert Stephan, Vice President, Research and Physician Society, and Jan Heybroek, President of MDoutlook. All Rights Reserved ©2016. All registered trademarks are the property of their respective owners.

Clinical Impact of New Data Announcements in Chicago 2016

With another meeting of the American Society of Clinical Oncology® behind us, the MDoutlook disease analyst team is set to launch our 8th annual OncoPoll™ series measuring the immediate clinical impact of new data presented at the 2016 Annual Meeting in Chicago.

The largest gathering of cancer treaters in the world (more than 37,000 professionals) saw a number of really interesting announcements. In addition, a great emphasis was placed on the need for intensified collaboration between cancer treaters, researchers, life sciences organizations and advocacy organizations.

Since our inception in 2008, MDoutlook has spearheaded this global collaboration and connecting those involved in the management of cancer in meaningful ways. We now have developed the largest panel of cancer treaters in the world (>95,000!) and offer unrivaled access to engage oncology-focused clinicians in targeted ways.

Watch this space for the updates from our OncoPoll™ research. The first reports will be available on this website later this month.

Submitted by Dr. Robert Stephan, Vice President, Research and Physician Society, and Jan Heybroek, President of MDoutlook. All Rights Reserved ©2016. All registered trademarks are the property of their respective owners.

Global Physician Expectations for the Upcoming Cancer Meeting in Chicago

Almost all of the recent buzz in oncology is focused on the 2016 ASCO Annual Meeting®, which is starting this Friday in Chicago. In order to see how this information is being received by oncologists, we asked our panel of physicians a simple 2-question survey: “Are you planning to attend this year’s meeting in Chicago?” and “About which therapy track(s) are you most excited?”.

MDoutlook® are pleased to share excerpts from this most recent MDoutlook’s OncoPoll™ on the oncologists’ expectations leading into the 2016 Annual Meeting.

OncoPoll™ Methodology

  • Primary research phase involved global survey to verified and validated medical, hematologic, surgical, and radiation oncologists within the proprietary MDoutlook® global cancer treater panel
  • Fielded: Monday May 30th – June 1st, 2016
  • Research via interactive web-based survey instruments, utilizing proven MDoutlook methodology and proprietary technology
  • Aided list of meeting tracks was provided from which to choose
  • Response: 147 oncologists from 30 different countries

Key Conclusions: Overall Pre-Meeting Expectations for the 2016 ASCO Annual Meeting

  • Overall, there is no general consensus as to which therapy area(s) will be the hottest this year. None of the tracks were selected by more than 50% of the respondents
  • Physicians are most excited about the new data in breast cancer, with the two breast cancer tracks both being within the top 3 most selected by physicians

PreASCO Excitement Ranking

Conclusions

  • The top mentioned track was Breast – Triple Negative / Cytotoxics / Local Therapy, with 44% of respondents choosing this as an area of excitement
  • Only the top 7 tracks were chosen by more than 30% of physicians

Pre-Chicago Excitement Regional View

Conclusions

  • Looking specifically at those tracks selected by more than 30% of the respondents, one gets the overall impression that the level of excitement is higher in the US than in other regions
  • Breast – Triple negative (TN) / Cytotoxics / Local Therapy was the only track selected by more than half of the respondents from any 1 region

Pre-Chicago Excitement Attending View

Conclusions

  • As expected, those planning to attend the annual meeting in Chicago have a higher level of excitement than those not planning on attending
    • Combining all of the differences, there is about 20% more excitement for those planning to attend
      • Exceptions are the hematologic areas, perhaps due to the upcoming European Hematology Association (EHA) meeting in 2 weeks
      • Areas with the largest difference between planned attendees and not are central nervous system tumors (16% vs. 5%), non-prostate GU (35% vs. 11%), and patient and survivor care (16% vs. 8%) [analysis not shown]

Meet us in Chicago

Please visit our booth on the exhibit floor (booth 4043) to discuss this and other oncology research activities.

Immediately following the Annual meeting, we will conduct our annual series of MDoutlook OncoPolls, to assess the immediate impact of the meeting on clinical practice. We plan to compare the results with the aforementioned analysis to gauge how these pre-meeting expectations held up. Please look for this report in the near future. Click here to download a PDF copy of this post.

Contact us to discuss your oncology intelligence needs at [email protected] or +1.404.496.4136. And check out our new website. Thank you!

Submitted by Dr. Robert Stephan, Vice President, Research and Physician Society, and Jan Heybroek, President of MDoutlook. All Rights Reserved ©2016. All registered trademarks are the property of their respective owners.